DrugBaron

APRIL 13, 2020

More than a month after the World Health Organisation declared COVID19 a global pandemic on 11th March we are still missing one crucial piece of data from our modelling: the fraction of people who have established productive immunity against the SARS-CoV2 virus.

Immune Response 100

Immune Response Virus Vaccine Production 100

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. The role of extracellular vesicles in COVID-19 virus infection [Internet]. Available from: [link]

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

The Pharma Data

SEPTEMBER 30, 2021

We anticipate to sharing developments from our leading vaccines pipeline which underscore our ongoing commitment to uncovering insights which will help prevent severe infectious diseases at every stage of life, especially in diseases with an unmet need like respiratory syncytial virus.”. Poster presentation number 1137. In the U.S.,

Vaccine 52

Vaccine Research Virus Disease 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. AR-711 (COVID-19). AR-201 (RSV infection).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

AUGUST 20, 2020

They individually completed a range of exercises, which included singing and speaking Happy Birthday at different pitches and volumes, in an operating theatre where there were no other aerosols present. ” SURVIVING THE VIRUS: ‘Our medical science is struggling to catch-up’ COVID-19: How are dentists coping?

Virus 52

Virus Science Research 52

Broad Institute

JULY 19, 2023

Previous methods introduce millions of AAV capsids — the outer shells of the virus that bind to target proteins — into animals and rely on iterative rounds of screening to find AAVs that reach specific cells. Scientists have engineered adeno-associated viruses (AAVs) to package and deliver gene therapies to cells in the body.

Therapies 98

Therapies Research Engineering Virus 98

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

MARCH 2, 2021

Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. Gilead Sciences, Inc. HIV Research. HCV Research.

Virus 40

Virus Treatment Science Trials 40

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

Drug Target Review

JANUARY 26, 2024

These ACE2-coated particles could be tested as an anti-viral therapeutic, and as sensors for detecting virus particles. Several of the mouse cell clones produced about 50 times more ACE2 than is normally present on mouse cells.

Production 114

Production DNA Virus Protein Expression 114

The Pharma Data

MARCH 9, 2021

and Shionogi Limited as shareholders, presented positive data from its phase IIa proof-of-concept study of the investigational maturation inhibitor GSK3640254 (GSK’254). These findings were presented today at the (virtual) 2021 Conference on Retroviruses and Opportunistic Infections (CROI).

Treatment 52

Treatment RNA Pharmacokinetics Virus 52

Drug Target Review

JULY 5, 2023

In the study presented at ASGCT, what were the specific findings regarding the synergistic killing of SKOV3 ovarian tumour cells by the iPSC-derived lymphoid and myeloid cells? What are the key advancements in nucleic-acid delivery and targeted gene insertion that Eterna and Factor Bioscience presented at the ASGCT?

Therapies 103

Therapies DNA Engineering Virus 103

The Pharma Data

DECEMBER 25, 2020

Furthermore, as these two cases did not travel outside of Canada , it is important to follow public health measures and limit contacts with others, to reduce the transmission of the virus and any of its variants in communities. The best way to prevent infection with any variant of COVID-19 is to follow public health measures.

Virus 40

Virus Compliance Government Laboratories 40

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. Findings from a leading-edge study called TRACERx have demonstrated how mutations that occur very early in the process of cancer genesis remain present in all cells of a growing tumour.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. Results will be presented at an upcoming scientific congress and are anticipated to form the basis of regulatory submissions.

Virus 40

Virus Trials Disease Hospitals 40

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 128

Therapies Virus DNA Clinical Trials 128

BMG Labtech

MARCH 11, 2024

ELISAs played a pivotal role in the early detection of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). If more analyte is present in the sample, increasing amounts of detection antibody and signaling enzyme bind to the analyte.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

Drug Target Review

AUGUST 25, 2023

However, in tissues where the 3 Hs are not present, the small molecule has anti-toxicity activity through 1) direct inhibition of the NLRP3 inflammasome, an inflammation starter and perpetuator, and 2) upregulation of the master antioxidant transcription factor, Nrf2. Also, unlike several other viruses, AdAPT-001 is deliverable systemically.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

Codon

AUGUST 27, 2024

” These are short sequences of DNA that are highly conserved, meaning they are likely to be present in a wide variety of sequences. While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus.

DNA 97

DNA Laboratories Hospitals Virus 97

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Virus Medical Schools Science 137

The Pharma Data

DECEMBER 5, 2020

The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. The new data presented today strengthen our conviction that SY-1425 has the potential to become the foundation of care for all RARA-positive patients,” said David A. Chief Medical Officer of Syros.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

Drug Target Review

JANUARY 3, 2024

Nanobodies are a novel and unique class of antigen-binding fragments, derived from naturally occurring heavy-chain-only antibodies present in the serum of camelids. This is because this blocks the transmission chain, preventing the virus from spreading from cell to cell. Viruses in the GII.4 4 norovirus.

Virus 64

Virus Immune Response Vaccine Disease 64

Codon

DECEMBER 12, 2024

It’s important to note that the 300-page report, while presenting detailed evidence for the potential harms of mirrored life, uses painstakingly speculative language. A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa. It gives humanity time to steer away.

DNA 102

DNA RNA Vaccine Virus 102

Codon

SEPTEMBER 29, 2024

Simple ones, but still… This presented the student with a tantalizing future: the ability to fully model how a cell reacted to genetic perturbations. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within.

Engineering 141

Engineering Virus DNA Therapies 141

PLOS: DNA Science

JANUARY 25, 2024

We can learn about life, past and present, anywhere we find DNA and determine its sequence. A recent report in PLOS ONE analyzes DNA from an adenovirus and a herpes virus discovered in preserved feces – coprolites – from 5,500 to 7,000 years ago at an archaeological site in Japan.

Disease 98

Disease DNA Science Virus 98

PLOS: DNA Science

AUGUST 22, 2024

The Genetic Explanation Doesn’t Work The narrative returns to the present. As he trekked around the botanical gardens, he killed every living thing that he touched, including the canary-in-the-coal-mine banyan trees and himself. And that’s where the gaff comes in. TMV is a common pathogen used in early molecular biology research.

DNA 71

DNA Virus Organic Chemistry Science 71

Drug Target Review

NOVEMBER 24, 2023

The use of nanoparticles, which are around the size of a virus particle, is a very promising delivery method for overcoming chemotherapy issues. Macrophages typically consume and clear pathogens and then present the pathogen parts to T cells. The T cells then give an antigen-specific response to recognise that specific pathogen.

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

PLOS: DNA Science

JUNE 13, 2024

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. Her points: 1. Coincidence? I’ve never thought so. RaTG13 shares about 96.1%

Virus 52

Virus RNA DNA Science 52

Drug Target Review

OCTOBER 25, 2023

Preeclampsia may present at any gestation but is more commonly encountered in the third trimester. A human foetus contains genetic material from both parents, which makes it partly foreign to the pregnant person’s body. Many of these adaptations happen within the decidua, tissue that surrounds and interacts with the placenta.

Treatment 105

Treatment Virus Research Science 105

The Pharma Data

MAY 15, 2023

CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV) Gilead Sciences, Inc. People living with HDV have had very limited treatment options and without treatment, they often rapidly progress to severe liver disease or liver cancer.

Virus 40

Virus Marketing Treatment Science 40

The Pharma Data

MARCH 29, 2022

Once approved, this compound could be used in combination with already available drugs that inhibit the virus’ replication, to provide a stronger defense against COVID-19 variants of concern,” says Dr. Jean, founder of FINDER, the state-of-the-art level three biocontainment facility where the work on SARS-CoV-2 variants was conducted.

Virus 52

Virus Small Molecule Clinical Trials Research 52

The Pharma Data

DECEMBER 22, 2020

“The variant might already be present here and observed soon,” Lorenzo-Redondo said. “Theoretically, new mutations can impact vaccine efficacy as in other viruses, but the low mutation rate of this virus compared to others like flu or HIV-1 makes this more difficult,” he explained. and the U.K. .

Virus 52

Virus Vaccine Immune Response Treatment 52

The Pharma Data

DECEMBER 10, 2020

The conference was held in the early days of the outbreak, even before most people knew of the dangers of the virus and certainly before mask wearing and social distancing was recommended. It was initially reported that three Biogen employees who attended that meeting had tested positive for the virus.

Virus 52

Virus Hospitals Research Science 52

The Pharma Data

SEPTEMBER 28, 2020

By boosting the natural immune response of the ferrets with our treatment, we’ve seen a rapid eradication of the virus,” explained Dr Christophe Demaison, Managing Director at Ena Respiratory. “If If humans respond in a similar way, the benefits of treatment are two-fold.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

DrugBank

JULY 18, 2024

For instance, the influenza virus is notorious for its ability to undergo antigenic drift, accumulating mutations in its surface proteins that can render existing vaccines less effective.  This long clinical trial process, while essential, can present an approval bottleneck in pandemic or disease outbreak scenarios.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

DrugBank

MARCH 12, 2025

Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. This customized approach is particularly valuable in oncology, where tumor heterogeneity presents significant challenges for traditional therapies.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97